Addressing the rising trend of high-risk pulmonary embolism mortality: Clinical and research priorities

Acad Emerg Med. 2024 Mar;31(3):288-292. doi: 10.1111/acem.14859. Epub 2024 Feb 21.

Abstract

Background: Deaths from high-risk pulmonary embolism (PE) appear to have increased in the US over the last decade. Modifiable risks contributing to this worrisome trend present opportunities for physicians, researchers, and healthcare policymakers to improve care.

Methods: We sought to contextualize contemporary, high-risk PE epidemiology and examine clinical trials, quality improvement opportunities, and healthcare policy initiatives directed at reducing mortality.

Results: We observed significant and modifiable excess mortality due to high-risk PE. We identified several opportunities to improve care including: (1) rapid translation of forthcoming data on reperfusion strategies into clinical practice; (2) improved risk stratification tools; (3) quality improvement initiatives to address presumptive anticoagulation practice gaps; and (3) adoption of health policy initiatives to establish pulmonary embolism response teams and address the social determinants of health.

Conclusion: Addressing knowledge and practice gaps in intermediate and high-risk PE management must be prioritized and informed by forthcoming high-quality data. Implementation efforts are needed to improve acute PE management and resolve treatment disparities.

Keywords: catheter directed thrombolysis; health care disparities; pulmonary embolism; quality improvement; systemic thrombolysis.

MeSH terms

  • Fibrinolytic Agents* / therapeutic use
  • Humans
  • Pulmonary Embolism* / drug therapy
  • Research
  • Thrombolytic Therapy
  • Treatment Outcome

Substances

  • Fibrinolytic Agents